drugset / Trial / NCT00045292

Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

NCT00045292

RandomizedDouble-blindSupportive care

Summary

RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of valacyclovir in preventing cytomegalovirus in patients who are undergoing donor stem cell transplantation.

Timeline

Start
2002-04
Primary completion
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Valacyclovir Unknown Oral
Background Acyclovir Small molecule Intravenous

Indications